选择性AVP受体拮抗剂托伐普坦的药理及应用评价  

Evaluation of Clinical Application and Pharmacology of Selective AVP Receptor Antagonist Tolvaptan

作　　者：齐菲[1] 张士红[1] 

机构地区：[1]大连市中心医院,辽宁大连116033

出　　处：《医学与哲学（B）》2016年第2期63-66,共4页Medicine & Philosophy(B)

摘　　要：在心力衰竭、肝硬化腹水等稀释性低钠血症患者治疗中,了解新型选择性精氨酸血管加压素(AVP)受体拮抗剂托伐普坦的药理作用,探讨临床应用经验。通过类比同类药物,寻找相关药理学、循证医学证据,说明托伐普坦对血管加压素V2受体具有高选择性,排水不排钠,对血压、心率、电解质、肾脏功能影响小等优越的药理学特性,在各种原因引起的高血容量或正常血容量的低钠血症的治疗领域应用前景广阔,但对内分泌肿瘤等其他适应证仍有待于开发,其用药安全性需要临床实践进一步观察评价。To explore the pharmacological effects and evaluate the clinical application and experience of tolvaptan, a new generation of selective vasopressin receptor antagonist in the treatment of low sodium blood of patients, who get heart failure, liver cirrhosis ascites dilution etc. Through the methods of analoging similar drugs, gathering tolvaptan＇s pharmacology characteristic and follow the medical based evidences, it shows that tolvaptan, the high selectivity of the vasopressin V2 receptor, with many special advantages of the pharmacological characteristics, such as excluding moisture but sodium, little influence about blood pressure, heart rate, electrolyte, renal function etc. Tolvaptan has broad prospects in the treatment of high blood volume or normal blood volume caused by various reasons, but it is still needed to develop in endocrine tumors and other indications. The security needs to be further observed and evaluated.

关 键 词：选择性精氨酸血管加压素受体拮抗剂 托伐普坦 低钠血症 

分 类 号：R969.3[医药卫生—药理学]